David J. Benjamin, MD
@DavidBenjaminMD
Followers
510
Following
6K
Statuses
179
Medical oncologist and researcher with interests in genitourinary cancers and health policy. Tweets are my own views, and are not medical advice.
Orange County, CA
Joined April 2021
Was a pleasure to talk with @RinaNakanoTV of @kcalnews @CBSNews about our @JCOOP_ASCO publication on cancer's portrayal in #movies. Several aspects including #cancer type, treatment and prognosis significantly diverge from reality. Link (video):
1
2
26
RT @PGrivasMDPhD: Looking forward to reviewing this editorial. Timely since TROPiCS04 paper coming very soon, stay tuned :-) @tompowles1 @U…
0
2
0
Why did sacituzumab govitecan fail in the TROPiCS-04 study for advanced urothelial carcinoma? In @EurUrolOncol, we discuss the potential roles of G-CSF, dosing approaches, and differences in patient population compared to the TROPHY-U-01 trial. Link:
3
14
26
@drenriquegrande @DrRanaMcKay Thank you Dr. Grande! Major credit goes to @carisls scientist Dr. Tolu Adeyelu and the Caris team for their work on this endeavor.
0
0
4
RT @drenriquegrande: Amazing piece of work by @DavidBenjaminMD, @DrRanaMcKay and colls. with impact in daily practice: urachal tumors appr…
0
11
0
@montypal @carisls @DrRanaMcKay @ArashRezazadeh6 @SoCalGUResearch Absolutely, would be happy to do so!
0
0
0
RT @montypal: Announcing #SoCalGU25, which will be held on February 28, 2025. This consortium of GU #oncology investigators bridges efforts…
0
23
0
Thank you Dr. Jain and @DAVAonc for the opportunity to discuss the role of maintenance avelumab in advanced urothelial carcinoma. Identifying patient preferences (balancing survival and quality of life) may help in pairing the right individual with the right regimen.
2
0
11
Congratulations @mjmoussa_ @OAlhalabiMD @DocMattCampbell & the @MDAndersonNews team! Thank you for linking our @Sage_Raretumors review.
⏰TODAY at #SITC2024 (Poster #516) - @OAlhalabiMD @DocMattCampbell @MDAndersonNews 👉Reports of clinical activity of IO in urachal cancer is limited to a few case reports (@DavidBenjaminMD et al, Rare Tumors 2023, PMID 37465663) 👉Honored to share our experience w/ single-agent & combination IO in both urachal & non-urachal adenocarcinoma of the bladder, ft. clinical & molecular insights in this 1⃣st-ever series in the literature 🔗
1
2
6
RT @oncodaily: The importance of patient selection criteria in treating advanced urothelial carcinoma - @DavidBenjaminMD
@EurUrolOncol @Ar…
0
1
0
In @EurUrolOncol, @ArashRezazadeh6 and I discuss the importance of patient selection criteria for determining the most appropriate regimen (EV-302 vs. CheckMate 901 vs. JAVELIN Bladder 100) in treating advanced urothelial carcinoma. Link (full text):
1
3
9
In European Journal of Cancer, @VPrasadMDMPH and I discuss deviations in baseline & surveillance imaging in recent NSCLC trials such as #LAURA. Despite LAURA's sponsor acknowledging CT can understage NSCLC in the trial protocol, the study did not require standard-of-care PET/CT.
1
6
23
RT @VPrasadMDMPH: Just out @DavidBenjaminMD and I explain how inadequate staging and excess scans create false impressions of recent drugs…
0
11
0
Not surprised as our @CancerMedicineJ systematic review & meta-analysis done with @AlysonHaslam and @VPrasadMDMPH showed mostly a lack of benefit for cardiovascular drugs re-purposed in oncology over the past twenty years. #ESMO24 #ESMOAmbassadors Link:
No Overall survival benefits of adding metformin to ADT systemic therapy in patients with mHSPC #ProstateCancer in the STAMPEDE trial👉excellent talk by @Silke_Gillessen at #ESMO24 @myESMO 👇Conclusions👇 @urotoday @PCF_Science @OncoAlert @CR_UK
0
6
21
RT @BMJOncology: It is critical for individuals with cancer as well as family members and caregivers to be cognizant that previous exposur…
0
5
0
Credit to @peterbachmd for inspiring us to look at the state of supportive care in oncology. Now at #ESMO24, we find: → Therapeutic trials outnumber supportive care 25 to 1 → Industry sponsors only 1.4% of supportive care trials More findings are available at poster 1901P.
Do we have the right priorities in oncology #ESMO2023 #ESMO23 - pictures taken a few minutes apart. Supportive care and Investigational therapy poster areas. Clinically these two are intertwined.
4
14
40
Many thanks to the JCO OP editorial office for allowing us to present this previously unpublished data. Link to our original publication:
0
3
2
The FDA’s 1st approval of a subcutaneous immune checkpoint inhibitor is an opportunity to revisit our @trendscancer publication. We discuss advantages & disadvantages with subcutaneous administration versus the traditional intravenous route. Link:
FDA approves subcutaneous form of atezolizumab for use where IV already approved (including NSCLC and SCLC). Based on IMscin001 showing OS, RR, PROs, safety were similar with far shorter administration time.
0
3
8